A single-center comparison of our initial experiences in treating penile and urethral cancer with video-endoscopic inguinal lymphadenectomy (VEIL) and later experiences in melanoma cases.
endoscopy
lymph node excision
melanoma
penile neoplasms
urethral neoplasms
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
08
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
Video-endoscopic inguinal lymphadenectomy (VEIL) is a minimally invasive approach that is increasingly indicated in oncological settings, with mounting evidence for its long-term oncological safety. To present our single-center experience of treating penile and urethral cancer with VEIL, as well as its more recent application in melanoma patients. We prospectively recorded our experiences with VEIL from September 2010 to July 2018, registering the patient primary indication, surgical details, complications, and follow-up. Twenty-nine patients were operated in one (24) or both (5) groins; 18 had penile cancer, 1 had urethral cancer, and 10 had melanoma. A mean 8.62 ± 4.45 lymph nodes were removed using VEIL and of these, an average of 1.00 ± 2.87 were metastatic; 16 patients developed lymphocele and 10 presented some degree of lymphedema; there were no skin or other major complications. The median follow-up was 19.35 months; there were 3 penile cancer patient recurrences in the VEIL-operated side. None of the melanoma patients presented a lymphatic inguinal recurrence. VEIL is a minimally invasive technique which appears to be oncologically safe showing fewer complications than open surgery. However, complications such as lymphorrhea, lymphocele, or lymphedema were not diminished by using VEIL.
Sections du résumé
Background
UNASSIGNED
Video-endoscopic inguinal lymphadenectomy (VEIL) is a minimally invasive approach that is increasingly indicated in oncological settings, with mounting evidence for its long-term oncological safety.
Objectives
UNASSIGNED
To present our single-center experience of treating penile and urethral cancer with VEIL, as well as its more recent application in melanoma patients.
Methods
UNASSIGNED
We prospectively recorded our experiences with VEIL from September 2010 to July 2018, registering the patient primary indication, surgical details, complications, and follow-up.
Results
UNASSIGNED
Twenty-nine patients were operated in one (24) or both (5) groins; 18 had penile cancer, 1 had urethral cancer, and 10 had melanoma. A mean 8.62 ± 4.45 lymph nodes were removed using VEIL and of these, an average of 1.00 ± 2.87 were metastatic; 16 patients developed lymphocele and 10 presented some degree of lymphedema; there were no skin or other major complications. The median follow-up was 19.35 months; there were 3 penile cancer patient recurrences in the VEIL-operated side. None of the melanoma patients presented a lymphatic inguinal recurrence.
Conclusions
UNASSIGNED
VEIL is a minimally invasive technique which appears to be oncologically safe showing fewer complications than open surgery. However, complications such as lymphorrhea, lymphocele, or lymphedema were not diminished by using VEIL.
Identifiants
pubmed: 36225221
doi: 10.3389/fsurg.2022.870857
pmc: PMC9548630
doi:
Types de publication
Journal Article
Langues
eng
Pagination
870857Informations de copyright
© 2022 Gómez-Ferrer, Collado, Ramírez, Domínguez, Casanova, Mir, Wong, Marenco, Nagore, Soriano and Rubio-Briones.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Esp Urol. 2006 Oct;59(8):849-52
pubmed: 17153511
Int Braz J Urol. 2013 Jul-Aug;39(4):587-92
pubmed: 24054388
Indian J Surg Oncol. 2012 Sep;3(3):257-61
pubmed: 23997519
Urol Ann. 2016 Jul-Sep;8(3):281-5
pubmed: 27453648
J Endourol. 2013 May;27(5):657-61
pubmed: 23268699
J Am Coll Surg. 2014 Apr;218(4):620-6
pubmed: 24560569
Rev Panam Salud Publica. 2017 Nov 30;41:e117
pubmed: 31384255
J Endourol. 2008 Aug;22(8):1687-91
pubmed: 18657031
Ann Surg Oncol. 2011 Apr;18(4):977-82
pubmed: 21184190
Zhonghua Yi Xue Za Zhi. 2013 Jun 4;93(21):1653-6
pubmed: 24125676
Int J Gynecol Cancer. 2017 Jan;27(1):159-165
pubmed: 27870714
Eur Urol. 2015 Jan;67(1):142-150
pubmed: 25457021
Urology. 2018 Mar;113:79-84
pubmed: 29155185
Eur J Surg Oncol. 2015 Mar;41(3):274-81
pubmed: 25583458
Ann Surg Oncol. 2010 Mar;17(3):731-7
pubmed: 20183910
J Robot Surg. 2016 Dec;10(4):369-372
pubmed: 27173971
Oncol Lett. 2015 Feb;9(2):752-756
pubmed: 25621046
J Endourol. 2013 Apr;27(4):497-503
pubmed: 23067251
Chin Med J (Engl). 2013 Aug;126(16):3181-3
pubmed: 23981634
J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S152
pubmed: 27678857
Chin J Cancer Res. 2012 Jun;24(2):90-6
pubmed: 23359765
J Plast Surg Hand Surg. 2013 Sep;47(4):248-51
pubmed: 23627646
Urology. 2009 Jan;73(1):167-70; discussion 170-1
pubmed: 18829076
PLoS One. 2015 Oct 23;10(10):e0140873
pubmed: 26496391
J Minim Invasive Gynecol. 2011 Sep-Oct;18(5):644-50
pubmed: 21872170
Br J Surg. 2016 Jul;103(8):1026-32
pubmed: 27146356
Eur Urol. 2009 May;55(5):1075-88
pubmed: 19264390
World J Surg Oncol. 2013 Feb 22;11:42
pubmed: 23432959
Ann Oncol. 2019 Dec 1;30(12):1884-1901
pubmed: 31566661
Curr Urol Rep. 2014 Jun;15(6):412
pubmed: 24756453
Int Braz J Urol. 2008 Nov-Dec;34(6):725-30; discussion 730-3
pubmed: 19111077
World J Urol. 2009 Apr;27(2):213-9
pubmed: 19221761
Int J Gynecol Cancer. 2016 Nov;26(9):1706-1711
pubmed: 27575632
Am Surg. 2017 Aug 1;83(8):e332-334
pubmed: 28822379
Int Braz J Urol. 2006 May-Jun;32(3):316-21
pubmed: 16813678
Int J Gynecol Cancer. 2017 Nov;27(9):1983-1989
pubmed: 28885273
Cancer. 2010 Jun 15;116(12):2960-6
pubmed: 20564401
Int Braz J Urol. 2012 Jul-Aug;38(4):567-8
pubmed: 22951170
J Endourol. 2007 Apr;21(4):364-7; discussion 367
pubmed: 17451323
Ann Surg Oncol. 2017 Oct;24(11):3237-3244
pubmed: 28770482
Int J Surg Case Rep. 2014;5(8):455-8
pubmed: 24973526
Int Braz J Urol. 2013 Nov-Dec;39(6):893; discussion 894
pubmed: 24456782
J Urol. 2007 Mar;177(3):953-7; discussion 958
pubmed: 17296386
Urology. 2017 Aug;106:113-118
pubmed: 28450202
J Endourol. 2018 Jan;32(1):66-72
pubmed: 29256632
Gynecol Oncol. 2017 Jan;144(1):225-226
pubmed: 27871722
Urology. 2009 Jun;73(6):1424-5
pubmed: 19482164
Zhonghua Yi Xue Za Zhi. 2014 Jan 7;94(1):39-42
pubmed: 24721305
Ann Surg Oncol. 2013 Jan;20(1):340-5
pubmed: 22875645